[Passage of cefotiam into prostatic tissue].

It was already known that certain antibiotics can penetrate prostatic tissue, but the specific behavior of cefotiam remained unclear. No prior work had resolved how quickly cefotiam reaches prostatic tissue after intravenous administration. This gap motivated researchers to investigate the drug’s diffusion dynamics. Prior studies suggested antibiotics like cefotiam may reach therapeutic levels in prostatic tissue. However, the timing and extent of this penetration were not fully characterized. This uncertainty drove the need for direct measurement of drug concentrations in tissue and serum. The study aimed to address this gap by analyzing samples from patients undergoing prostate surgery. The lack of data on cefotiam’s half-life in prostatic tissue also created a need for further investigation.

The study aimed to assess how cefotiam distributes into prostatic tissue following intravenous administration. Researchers focused on measuring drug concentrations in both serum and tissue at specific time intervals. They wanted to determine the drug’s half-life in prostatic tissue compared to serum. The goal was to confirm whether cefotiam reaches sufficient levels in the prostate for therapeutic use. The timing of drug saturation in tissue was also a key concern. This information could help guide dosing strategies for prostatitis treatment. The study sought to provide evidence for the drug’s effectiveness in this context. The findings could support clinical recommendations for cefotiam use in urological infections.

Researchers collected tissue and serum samples from 12 patients after a single 2 g intravenous dose of cefotiam. Samples were taken at 20, 30, and 90 minutes post-administration. Patients had undergone transabdominal prostatectomy for prostatic adenoma. Cefotiam concentrations were measured using high-performance liquid chromatography (HPLC). Mean concentrations were calculated for both serum and prostatic tissue. Time intervals were chosen to capture early drug distribution patterns. The elimination half-life was calculated for both tissue and serum compartments. This approach allowed direct comparison of drug kinetics in different body compartments.

At 20 minutes, mean serum concentration was 157 ± 39 mg/ml and prostatic tissue was 42 ± 23 mg/g. By 30 minutes, serum dropped to 77 ± 52 mg/ml while tissue increased to 54 ± 2 mg/g. At 90 minutes, serum was 36 ± 21 mg/ml and tissue was 16 ± 18 mg/g. The elimination half-life in serum was 1 hour 39 minutes. In prostatic tissue, it was 1 hour 10 minutes. These values suggest drug saturation occurs in tissue by 30 minutes. Tissue concentrations remained above therapeutic thresholds for a significant period. The results confirm cefotiam’s ability to diffuse into prostatic tissue effectively.

The authors propose that cefotiam reaches sufficient concentrations in prostatic tissue for therapeutic use. The data suggest the drug’s half-life in tissue is shorter than in serum. This finding implies faster elimination from prostatic tissue compared to systemic circulation. The results support the expectation of effective treatment for prostatitis with cefotiam. The timing of drug saturation in tissue suggests optimal dosing may occur within the first 30 minutes. The study confirms the drug’s satisfactory diffusion into prostatic tissue. These findings may inform clinical guidelines for antibiotic use in urological infections. The authors suggest further research could explore long-term effects and dosing intervals.